New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 21, 2014
07:18 EDTMON, TKMRTekmira receives $14.5M milestone payment from Monsanto
Tekmira Pharmaceuticals (TKMR) confirmed that it has received $14.5M of the net $16.5M in near term payments as outlined in the terms of an option agreement signed with Monsanto (MON), which supports the application of Tekmira's proprietary delivery technology and related intellectual property for use in agriculture. The agreement follows Monsanto's initial testing of Tekmira's proprietary delivery technology and the demonstration of initial positive results from use of that technology in the field of agriculture. The companies' agreement and research collaboration is focused on the development of new innovative biological solutions for farmers, which have the potential to provide new options for sustainable pest, virus and weed control.
News For TKMR;MON From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 26, 2015
07:25 EDTMONMonsanto volatility elevated into Q2 and outlook
Subscribe for More Information
March 25, 2015
19:34 EDTTKMRTekmira 'encouraged' by new preclinical data on TKM-HTG
Subscribe for More Information
March 23, 2015
13:39 EDTMONMonsanto addresses assessment on glyphosate by IARC
Monsanto Company further addressed last week’s assessment on glyphosate by the International Agency for Research on Cancer. “We are outraged with this assessment,” said Dr. Robb Fraley, Monsanto’s Chief Technology Officer. “This conclusion is inconsistent with the decades of ongoing comprehensive safety reviews by the leading regulatory authorities around the world that have concluded that all labeled uses of glyphosate are safe for human health. This result was reached by selective ‘cherry picking’ of data and is a clear example of agenda-driven bias.” The repeated safety assessments by regulatory authorities over the last three decades have formed the foundation for the long history of safe, highly effective use of this important agricultural tool in more than 160 countries around the world. Decisions regarding product safety and approvals for pesticides are governed by regulatory agencies such as the U.S. Environmental Protection Agency and the European Commission, as well as independent scientific advisory bodies such as the European Food Safety Authority. IARC has no regulatory authority and its decision does not impact glyphosate’s label, current registration or use. “Safety is the top priority for every person who works at Monsanto. Glyphosate-based herbicides on the market meet the rigorous standards set by the regulatory and health authorities who work every day to protect human health, and we want our customers and consumers to be assured of these evaluations,” Fraley added. In contrast to the comprehensive review that regulators around the world have completed over three decades, IARC issued its classification based on a limited data review after hours of discussion at a one-week meeting. Further, IARC is one of four programs within the WHO that have reviewed the safety of glyphosate and their classification is inconsistent with the assessments of the other programs. Two of the WHO programs – the Core Assessment Group and the International Programme on Chemical Safety – both concluded glyphosate is not carcinogenic. The WHO Guidelines for Drinking-Water Quality program concluded glyphosate does not represent a hazard to human health.
12:17 EDTMONOn The Fly: Midday Wrap
Subscribe for More Information
11:21 EDTMONOrigin Agritech shares spike higher after report of possible takeover interest
Subscribe for More Information
11:07 EDTMONMonsanto weakness on Glyphosate WHO claims overblown, says Piper Jaffray
Subscribe for More Information
09:46 EDTMONScotts Miracle-Gro slips after report on Monsanto herbicide
Subscribe for More Information
March 22, 2015
16:22 EDTMONChina looks to develop seed program to fend off foreign competition, WSJ says
Subscribe for More Information
14:27 EDTMONWHO says herbicide marketed by Monsanto likely carcinogenic, WSJ says
A World Health Organization agency said Friday that Glyphosate, a herbicide marketed by Monsanto under the Roundup brand and other companies, has the potential to cause cancer in humans, says the Wall Street Journal. Monsanto contested the findings saying that glyphosate is safe if used as recommended by its label and that decades of extensive study have proven its safety, added the Wall Street Journal. Reference Link
March 20, 2015
06:17 EDTTKMRTekmira 7.5M share Secondary priced at $20.25
Subscribe for More Information
March 19, 2015
09:20 EDTTKMROn The Fly: Pre-market Movers
Subscribe for More Information
March 18, 2015
18:32 EDTTKMROn The Fly: After Hours Movers
UP AFTER EARNINGS: Guess (GES), up 12.4% after reporting fourth quarter results and guidance... Shoe Carnival (SCVL), up 10%... NQ Mobile (NQ), up 9.1%... Tilly's (TLYS), up 1.3%... Cintas (CTAS), up 1.3% after reporting quarterly results and raising fiscal 2015 guidance. DOWN AFTER EARNINGS: Williams-Sonoma (WSM), down 4.1%... Jabil Circuit (JBL), down 1.8%... Juno Therapeutics (JUNO), down 3.3%. ALSO LOWER: Concert Pharmaceuticals (CNCE), down 4.4% after filing to sell common stock... Tekmira Pharmaceuticals (TKMR), down 3.7% after filing to sell 6M shares of common stock.
16:19 EDTTKMRTekmira files to sell 6M shares of common stock
Leerink Partners LLC and RBC Capital Markets LLC are acting as joint lead book-runners for the offering. Nomura is acting as a book-runner for the offering. Co-managers for the offering are: JMP Securities, Wedbush PacGrow Life Sciences and Lazard Frères & Co.
14:37 EDTMONMonsanto and midwest, southeast wheat farmers reach settlement agreement
Subscribe for More Information
March 16, 2015
11:58 EDTMONDuPont retreats after Bank of America two notch downgrade to sell
Subscribe for More Information
March 12, 2015
16:38 EDTTKMRTekmira reports FY14 EPS ($1.80), one estimate (31c)
Subscribe for More Information
07:25 EDTMONMonsanto volatility elevated into Q2 and outlook
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use